Astrazeneca (AZN) Share Price

Best deals to access real time data!
Silver Monthly Subscription for only ~~£17.37~~
Level 2 Basic Monthly Subscription for only ~~£62.08~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type	Stock ISIN	Stock Description
Astrazeneca Plc	AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	Price Change %	Stock Price	High Price	Low Price	Open Price	Close Price	Last Trade
	-49.00	-0.72%	6,772.00	6,860.00	6,763.00	6,821.00	6,821.00	16:35:11

more quote information »

Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Astrazeneca AZN Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
25/07/2019	Interim	USX	90	31/12/2017	31/12/2018	08/08/2019	09/08/2019	09/09/2019	0
14/02/2019	Final	USX	190	31/12/2017	31/12/2018	28/02/2019	01/03/2019	27/03/2019	280
26/07/2018	Interim	USX	90	31/12/2017	31/12/2018	09/08/2018	10/08/2018	10/09/2018	0
02/02/2018	Final	USX	190	31/12/2016	31/12/2017	15/02/2018	16/02/2018	19/03/2018	280
27/07/2017	Interim	USX	90	31/12/2016	31/12/2017	10/08/2017	11/08/2017	11/09/2017	0
02/02/2017	Final	USX	190	31/12/2015	31/12/2016	16/02/2017	17/02/2017	20/03/2017	280
28/07/2016	Interim	USX	90	31/12/2015	31/12/2016	11/08/2016	12/08/2016	12/09/2016	0
04/02/2016	Final	USX	190	31/12/2014	31/12/2015	18/02/2016	19/02/2016	21/03/2016	280
30/07/2015	Interim	USX	90	31/12/2014	31/12/2015	13/08/2015	14/08/2015	14/09/2015	0
05/02/2015	Final	USX	190	31/12/2013	31/12/2014	19/02/2015	20/02/2015	23/03/2015	280
31/07/2014	Interim	USX	90	31/12/2013	31/12/2014	13/08/2014	15/08/2014	15/09/2014	0
06/02/2014	Final	USX	190	31/12/2012	31/12/2013	19/02/2014	21/02/2014	24/03/2014	280
01/08/2013	Interim	USX	90	31/12/2012	31/12/2013	14/08/2013	16/08/2013	16/09/2013	0
31/01/2013	Final	USX	190	31/12/2011	31/12/2012	13/02/2013	15/02/2013	18/03/2013	280
26/07/2012	Interim	USX	90	31/12/2011	31/12/2012	08/08/2012	10/08/2012	10/09/2012	0
02/02/2012	Final	USX	195	31/12/2010	31/12/2011	15/02/2012	17/02/2012	19/03/2012	280
28/07/2011	Interim	USX	85	31/12/2010	31/12/2011	03/08/2011	05/08/2011	12/09/2011	0
27/01/2011	Final	USX	185	31/12/2009	31/12/2010	02/02/2011	04/02/2011	14/03/2011	255
29/07/2010	Interim	USX	70	31/12/2009	31/12/2010	02/08/2010	04/08/2010	13/09/2010	0
28/01/2010	Final	USX	171	31/12/2008	31/12/2009	03/02/2010	05/02/2010	15/03/2010	230
30/07/2009	Interim	USX	59	30/12/2008	30/06/2009	05/08/2009	07/08/2009	14/09/2009	0
29/01/2009	Final	USX	150	31/12/2007	31/12/2008	04/02/2009	06/02/2009	16/03/2009	205
31/07/2008	Interim	USX	55	30/12/2007	30/06/2008	08/08/2008	06/08/2008	15/09/2008	0
31/01/2008	Final	USX	135	31/12/2006	31/12/2007	06/02/2008	08/02/2008	17/03/2008	187
26/07/2007	Interim	USX	52	30/06/2006	30/06/2007	08/08/2007	10/08/2007	17/09/2007	0
01/02/2007	Final	USX	123	31/12/2005	31/12/2006	07/02/2007	09/02/2007	19/03/2007	172
27/07/2006	Interim	USX	49	30/12/2005	30/06/2006	09/08/2006	11/08/2006	18/09/2006	0
01/02/2006	Final	USX	92	31/12/2004	31/12/2005	08/02/2006	10/02/2006	20/03/2006	130
29/07/2005	Interim	USX	38	30/12/2004	30/06/2005	10/08/2005	12/08/2005	19/09/2005	0
27/01/2005	Final	USX	64.5	31/12/2003	31/12/2004	09/02/2005	11/02/2005	21/03/2005	94
22/07/2004	Interim	USX	29.5	30/12/2003	30/06/2004	11/08/2004	13/08/2004	20/09/2004	0
29/01/2004	Final	USX	54	31/12/2002	31/12/2003	18/02/2004	20/02/2004	06/04/2004	79.5
24/07/2003	Interim	USX	25.5	30/12/2002	30/06/2003	20/08/2003	22/08/2003	06/10/2003	0
30/01/2003	Final	USX	47	31/12/2001	31/12/2002	19/02/2003	21/02/2003	07/04/2003	70
25/07/2002	Interim	USX	23	30/12/2001	30/06/2002	21/08/2002	23/08/2002	07/10/2002	0
31/01/2002	Final	USX	47	31/12/2000	31/12/2001	20/02/2002	22/02/2002	08/04/2002	70
26/07/2001	Interim	USX	23	30/12/2000	30/06/2001	22/08/2001	24/08/2001	05/10/2001	0
08/02/2001	Final	USX	47	31/12/1999	31/12/2000	21/02/2001	23/02/2001	09/04/2001	70
01/08/2000	Interim	USX	23	30/12/1999	30/06/2000	04/09/2000	08/09/2000	23/10/2000	0
24/02/2000	Final	USX	47	31/12/1998	31/12/1999	06/03/2000	10/03/2000	17/04/2000	70
03/08/1999	Interim	USX	23	30/12/1998	30/06/1999	06/09/1999	10/09/1999	25/10/1999	0

Date	Subject
01/10/2019 08:30	arja: cheshire pets, sorry for delay in answering as I was abroad for a few days . It just means " no overhead resistance" when a share price breaks through to a higher level not seen previously . I notice AZN down in last day or so with disappointing announcement and share prices of drug companies can be volatile I guess as a lot of news flows . i am not sure if USA or UK is LEAD market for this stock . Read Full Thread Follow Reply
14/8/2019 07:16	ayl30: RNS today looks positive. Should help share price trend continue Read Full Thread Follow Reply
18/6/2019 13:01	bluemango: Meanwhile, share price only needs to put on just over 2% more and it will be surpassing all time high of £65.40. Good trials results and new approvals keep flowing through and should eventually be translated into earnings and dividend growth. Read Full Thread Follow Reply
18/7/2018 12:01	bountyhunter: http://uk.advfn.com/stock-market/london/astrazeneca-AZN/share-news/AstraZeneca-Increases-Drug-Stockpile-in-Preparatio/77885692 that's one way to reduce any potential initial WTO tariffs/bottlenecks! Read Full Thread Follow Reply
08/10/2017 12:51	cool druid: [...] Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS) By Alliance \| Fri, 6th October 2017 - 14:19 LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company. The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin. Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo. The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%. Merrill Lynch had a holding that was below the notable threshold prior to the purchase. Motif Bio shares were up 6% on Friday at 46.11 pence. By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance Read more: http://www.thisismoney.co.uk/money/investing/article-4955948/Advanced-Oncotherapy-enjoys-64-share-price-boost.html#ixzz4uoWb91d9 A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure. Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment Read Full Thread Follow Reply
30/7/2017 19:12	nw99: Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend." Read Full Thread Follow Reply
28/7/2017 15:10	minerve: My comment from yesterday: "Minerve 27 Jul '17 - 10:46 - 1954 of 1988 0 0 Edit This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675." Pretty good, huh? Read Full Thread Follow Reply
27/7/2017 10:46	minerve: This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675. Read Full Thread Follow Reply
27/7/2017 10:10	steeplejack: Well,I guess the analysts have run their adjustments of new discounted cash flow calculations on Mystic accounting for this giant setback/failure.The share price has retreated back to where it was end Feb.A correction of 15% on the day,is fairly unforgiving but understandable.I'm not selling but I'm unprepared to buy into a dead cat bounce or the wishful thinking of a bid.For now,there's consolation in the dividend. Read Full Thread Follow Reply
20/1/2017 17:26	philanderer: "Is Neil Woodford a fool to continue pumping money into Capita plc and AstraZeneca plc? 'Patience' AstraZeneca is Woodford's largest holding and an example of just how long he's prepared to be patient with a company he views as intrinsically undervalued. Earnings at the pharma group have suffered as a result of expiring patents on some of its top sellers and no improvement is expected to the bottom line until 2018. However, the company has maintained its dividend through this difficult period and offers a 5% yield at a current share price of around 4,400p. The dividend is forecast to start rising with the resumption of earnings growth in 2018 as a result of Astra's reinvigorated drugs pipeline. HTTP://money.aol.co.uk/2017/01/20/is-neil-woodford-a-fool-to-continue-pumping-money-into-capita-pl/ Read Full Thread Follow Reply

Date

Subject

01/10/2019
08:30

arja: cheshire pets, sorry for delay in answering as I was abroad for a few days . It just means " no overhead resistance" when a share price breaks through to a higher level not seen previously . I notice AZN down in last day or so with disappointing announcement and share prices of drug companies can be volatile I guess as a lot of news flows . i am not sure if USA or UK is LEAD market for this stock .

Read Full Thread

14/8/2019
07:16

ayl30: RNS today looks positive. Should help share price trend continue

Read Full Thread

18/6/2019
13:01

bluemango: Meanwhile, share price only needs to put on just over 2% more and it will be surpassing all time high of £65.40. Good trials results and new approvals keep flowing through and should eventually be translated into earnings and dividend growth.

Read Full Thread

18/7/2018
12:01